Differences in risk factors for breast cancer molecular subtypes in a population-based study

Xiaohong R. Yang, Mark E. Sherman, David L. Rimm, Jolanta Lissowska, Louise A. Brinton, Beata Peplonska, Stephen M. Hewitt, William F. Anderson, Neonila Szeszenia-Da̧browska, Alicja Bardin-Mikolajczak, Witold Zatonski, Richard Cartun, Daniza Mandich, Grzegorz Rymkiewicz, Marcin Ligaj, Stanislaw Lukaszek, Radzisaw Kordek, Montserrat García-Closas

Research output: Contribution to journalArticle

331 Citations (Scopus)

Abstract

Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor α, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95% confidence intervals. We observed that compared with the predominant luminal A tumors (69%), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8%) and basal-like (12%) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95% confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; P heterogeneity = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; P heterogeneity = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer.

Original languageEnglish (US)
Pages (from-to)439-443
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume16
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Breast Neoplasms
Population
Neoplasms
Odds Ratio
Keratin-5
Confidence Intervals
Menarche
Progesterone Receptors
Estrogen Receptors
Body Mass Index
Coloring Agents
Gene Expression

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Differences in risk factors for breast cancer molecular subtypes in a population-based study. / Yang, Xiaohong R.; Sherman, Mark E.; Rimm, David L.; Lissowska, Jolanta; Brinton, Louise A.; Peplonska, Beata; Hewitt, Stephen M.; Anderson, William F.; Szeszenia-Da̧browska, Neonila; Bardin-Mikolajczak, Alicja; Zatonski, Witold; Cartun, Richard; Mandich, Daniza; Rymkiewicz, Grzegorz; Ligaj, Marcin; Lukaszek, Stanislaw; Kordek, Radzisaw; García-Closas, Montserrat.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 16, No. 3, 03.2007, p. 439-443.

Research output: Contribution to journalArticle

Yang, XR, Sherman, ME, Rimm, DL, Lissowska, J, Brinton, LA, Peplonska, B, Hewitt, SM, Anderson, WF, Szeszenia-Da̧browska, N, Bardin-Mikolajczak, A, Zatonski, W, Cartun, R, Mandich, D, Rymkiewicz, G, Ligaj, M, Lukaszek, S, Kordek, R & García-Closas, M 2007, 'Differences in risk factors for breast cancer molecular subtypes in a population-based study', Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 3, pp. 439-443. https://doi.org/10.1158/1055-9965.EPI-06-0806
Yang, Xiaohong R. ; Sherman, Mark E. ; Rimm, David L. ; Lissowska, Jolanta ; Brinton, Louise A. ; Peplonska, Beata ; Hewitt, Stephen M. ; Anderson, William F. ; Szeszenia-Da̧browska, Neonila ; Bardin-Mikolajczak, Alicja ; Zatonski, Witold ; Cartun, Richard ; Mandich, Daniza ; Rymkiewicz, Grzegorz ; Ligaj, Marcin ; Lukaszek, Stanislaw ; Kordek, Radzisaw ; García-Closas, Montserrat. / Differences in risk factors for breast cancer molecular subtypes in a population-based study. In: Cancer Epidemiology Biomarkers and Prevention. 2007 ; Vol. 16, No. 3. pp. 439-443.
@article{9ab07f42e00349e99538dc726fcafcb3,
title = "Differences in risk factors for breast cancer molecular subtypes in a population-based study",
abstract = "Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor α, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95{\%} confidence intervals. We observed that compared with the predominant luminal A tumors (69{\%}), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8{\%}) and basal-like (12{\%}) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95{\%} confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; P heterogeneity = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; P heterogeneity = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer.",
author = "Yang, {Xiaohong R.} and Sherman, {Mark E.} and Rimm, {David L.} and Jolanta Lissowska and Brinton, {Louise A.} and Beata Peplonska and Hewitt, {Stephen M.} and Anderson, {William F.} and Neonila Szeszenia-Da̧browska and Alicja Bardin-Mikolajczak and Witold Zatonski and Richard Cartun and Daniza Mandich and Grzegorz Rymkiewicz and Marcin Ligaj and Stanislaw Lukaszek and Radzisaw Kordek and Montserrat Garc{\'i}a-Closas",
year = "2007",
month = "3",
doi = "10.1158/1055-9965.EPI-06-0806",
language = "English (US)",
volume = "16",
pages = "439--443",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Differences in risk factors for breast cancer molecular subtypes in a population-based study

AU - Yang, Xiaohong R.

AU - Sherman, Mark E.

AU - Rimm, David L.

AU - Lissowska, Jolanta

AU - Brinton, Louise A.

AU - Peplonska, Beata

AU - Hewitt, Stephen M.

AU - Anderson, William F.

AU - Szeszenia-Da̧browska, Neonila

AU - Bardin-Mikolajczak, Alicja

AU - Zatonski, Witold

AU - Cartun, Richard

AU - Mandich, Daniza

AU - Rymkiewicz, Grzegorz

AU - Ligaj, Marcin

AU - Lukaszek, Stanislaw

AU - Kordek, Radzisaw

AU - García-Closas, Montserrat

PY - 2007/3

Y1 - 2007/3

N2 - Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor α, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95% confidence intervals. We observed that compared with the predominant luminal A tumors (69%), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8%) and basal-like (12%) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95% confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; P heterogeneity = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; P heterogeneity = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer.

AB - Analysis of gene expression data suggests that breast cancers are divisible into molecular subtypes which have distinct clinical features. This study evaluates whether pathologic features and etiologic associations differ among molecular subtypes. We evaluated 804 women with invasive breast cancers and 2,502 controls participating in a Polish Breast Cancer Study. Immunohistochemical stains for estrogen receptor α, progesterone receptor, human epidermal growth factor receptors (HER2 and HER1), and cytokeratin 5 were used to classify cases into five molecular subtypes: luminal A, luminal B, HER2-expresing, basal-like, and unclassified. Relative risks were estimated using adjusted odds ratios and 95% confidence intervals. We observed that compared with the predominant luminal A tumors (69%), other subtypes were associated with unfavorable clinical features at diagnosis, especially HER2-expressing (8%) and basal-like (12%) tumors. Increasing body mass index significantly reduced the risk of luminal A tumors among premenopausal women (odds ratios, 0.71; 95% confidence intervals, 0.57-0.88 per five-unit increase), whereas it did not reduce risk for basal-like tumors (1.18; 0.86-1.64; P heterogeneity = 0.003). On the other hand, reduced risk associated with increasing age at menarche was stronger for basal-like (0.78; 0.68-0.89 per 2-year increase) than luminal A tumors (0.90; 0.95-1.08; P heterogeneity = 0.0009). Although family history increased risk for all subtypes (except for unclassified tumors), the magnitude of the relative risk was highest for basal-like tumors. Results from this study have shown that breast cancer risk factors may vary by molecular subtypes identified in expression studies, suggesting etiologic, in addition to clinical, heterogeneity of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=34047264801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047264801&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0806

DO - 10.1158/1055-9965.EPI-06-0806

M3 - Article

VL - 16

SP - 439

EP - 443

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -